Ronald Demuth
Fondateur chez Teal Ventures Management LLC
Profil
Ronald M.
Demuth is the founder of Teal Ventures Management LLC, which was founded in 2018.
He is currently the CEO, CFO & Secretary at Afraxis, Inc., a Director at Chromis Therapeutics, Inc., the President & Venture Partner at Torrey Pines Investment, Inc. since 2002, and the Chief Financial Officer at Viriom, Inc. since 2009.
Mr. Demuth's former positions include being the Chief Executive Officer at ChemDiv, Inc. from 2022 to 2024, the General Manager at Integrated Genomics, Inc. in 2002, and the Executive Administrator at The University of Chicago from 1988 to 1998.
Mr. Demuth's education history includes an undergraduate degree from Northern Illinois University and an undergraduate degree from the University of Iowa.
Postes actifs de Ronald Demuth
| Sociétés | Poste | Début |
|---|---|---|
Torrey Pines Investment, Inc.
 Torrey Pines Investment, Inc. Investment ManagersFinance Torrey Pines Investment, Inc (Torrey Pines Investment) is a venture capital firm is founded in 2002 by Nikolay Savchuk.The firm is headquartered San Diego, California. | President | 01/01/2002 |
Afraxis, Inc.
 Afraxis, Inc. BiotechnologyHealth Technology Afraxis, Inc. operates as a contract research organization (CRO), specializes in preclinical efficacy evaluations (in vivo and in vitro), neurotoxicity evaluations, and structure-efficacy relationship (SER)-driven medicinal chemistry. It develops Afraxis ESP, an enhanced spine analysis platform that quantifies the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing by neural synapses in the brain. The company was founded by Jay B. Lichter, Carmine Stengone, Susumu Tonegawa and Ben Vollrath in 2007 and is headquartered in San Diego, CA. | Directeur Général | - |
Teal Ventures Management LLC
 Teal Ventures Management LLC Investment ManagersFinance Teal Ventures Management LLC (Teal Ventures) is a venture capital firm founded by Nikolay Savchuk, Ron Demuth, and Eddie Rodriguez in 2018. The firm Headquartered in San Diego, California. | Fondateur | 01/05/2018 |
Chromis Therapeutics, Inc.
 Chromis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Chromis Therapeutics, Inc. focuses on the development of curative treatments for chronic HBV infection, based on its advanced proprietary drug design and discovery platform. Its CHR101 has a potential to eradicate HBV and to efficiently cure chronically infected HBV patients, as compared to drugs currently on the market. The company was founded by Vadim Bichko and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | - |
Viriom, Inc.
 Viriom, Inc. Miscellaneous Commercial ServicesCommercial Services Viriom, Inc. is a biotechnology company based in San Diego, CA. The company focuses on developing innovative therapies for infectious diseases, including HIV and COVID-19. Viriom's mission is to improve the lives of patients by providing effective and accessible treatments. Iain David Dukes has been the CEO of the company since 2019, leading the team in their efforts to advance the development of their pipeline and bring new therapies to market. | Directeur Financier/CFO | 01/07/2009 |
Anciens postes connus de Ronald Demuth
| Sociétés | Poste | Fin |
|---|---|---|
ChemDiv, Inc.
 ChemDiv, Inc. Miscellaneous Commercial ServicesCommercial Services ChemDiv, Inc. operates as a discovery and development contract research organization. It specializes in early and clinical development of anti-infectives and antivirals, oncologics, CNS, cardiometabolics, and anti-inflammatory therapies. The firm?s services include synthetic chemistry, structural biology and structure-based drug discovery, molecular modeling, medicinal chemistry, scale-up, biochemical and cellular assay development, analytical/bioanalytical platforms, ADME/tox, DMPK, and multiple in vivo efficacy/tox models. The company was founded by Alexander Ivachtchenko in 1991 and is headquartered in San Diego, CA. | Directeur Général | 01/01/2024 |
Integrated Genomics, Inc.
 Integrated Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Founded in 1997, Chicago-based Integrated Genomics™ specializes in research in microbial genomics, biochemistry, and gene expression. Its scientists has broad experience in both in silico and wet lab sequencing, research and development with more than 100 relevant publications in these areas. Integrated Genomics™ has particularly long-standing relationships and active research in the area of lactic acid bacteria and pathogenic microbes, as well as a broad customer base across industry, academic and government institutions. Integrated Genomics™' products and services are based on ERGO™, its web-based genome analysis platform. ERGO™ integrates proprietary functional genomic data, metabolic reconstructions, expression profiling, and biochemical and microbiological data with publicly available information. Focused on microbial genomics, ERGO™ provides better and faster identification of gene function across all organisms. In 2010 Integrated Genomics, Inc.'s business operations were transitioned to a new corporation, IG Assets, Inc. With the original Integrated Genomics' team, IG Assets continues to provide the same ERGO-based microbial genomic products and service. | Corporate Officer/Principal | 20/10/2002 |
| The University of Chicago | Corporate Officer/Principal | 01/01/1998 |
Formation de Ronald Demuth
| Northern Illinois University | Undergraduate Degree |
| University of Iowa | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
ChemDiv, Inc.
ChemDiv, Inc. Miscellaneous Commercial ServicesCommercial Services ChemDiv, Inc. operates as a discovery and development contract research organization. It specializes in early and clinical development of anti-infectives and antivirals, oncologics, CNS, cardiometabolics, and anti-inflammatory therapies. The firm?s services include synthetic chemistry, structural biology and structure-based drug discovery, molecular modeling, medicinal chemistry, scale-up, biochemical and cellular assay development, analytical/bioanalytical platforms, ADME/tox, DMPK, and multiple in vivo efficacy/tox models. The company was founded by Alexander Ivachtchenko in 1991 and is headquartered in San Diego, CA. | Commercial Services |
Afraxis, Inc.
Afraxis, Inc. BiotechnologyHealth Technology Afraxis, Inc. operates as a contract research organization (CRO), specializes in preclinical efficacy evaluations (in vivo and in vitro), neurotoxicity evaluations, and structure-efficacy relationship (SER)-driven medicinal chemistry. It develops Afraxis ESP, an enhanced spine analysis platform that quantifies the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing by neural synapses in the brain. The company was founded by Jay B. Lichter, Carmine Stengone, Susumu Tonegawa and Ben Vollrath in 2007 and is headquartered in San Diego, CA. | Health Technology |
Integrated Genomics, Inc.
Integrated Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Founded in 1997, Chicago-based Integrated Genomics™ specializes in research in microbial genomics, biochemistry, and gene expression. Its scientists has broad experience in both in silico and wet lab sequencing, research and development with more than 100 relevant publications in these areas. Integrated Genomics™ has particularly long-standing relationships and active research in the area of lactic acid bacteria and pathogenic microbes, as well as a broad customer base across industry, academic and government institutions. Integrated Genomics™' products and services are based on ERGO™, its web-based genome analysis platform. ERGO™ integrates proprietary functional genomic data, metabolic reconstructions, expression profiling, and biochemical and microbiological data with publicly available information. Focused on microbial genomics, ERGO™ provides better and faster identification of gene function across all organisms. In 2010 Integrated Genomics, Inc.'s business operations were transitioned to a new corporation, IG Assets, Inc. With the original Integrated Genomics' team, IG Assets continues to provide the same ERGO-based microbial genomic products and service. | Commercial Services |
Torrey Pines Investment, Inc.
Torrey Pines Investment, Inc. Investment ManagersFinance Torrey Pines Investment, Inc (Torrey Pines Investment) is a venture capital firm is founded in 2002 by Nikolay Savchuk.The firm is headquartered San Diego, California. | Finance |
Chromis Therapeutics, Inc.
Chromis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Chromis Therapeutics, Inc. focuses on the development of curative treatments for chronic HBV infection, based on its advanced proprietary drug design and discovery platform. Its CHR101 has a potential to eradicate HBV and to efficiently cure chronically infected HBV patients, as compared to drugs currently on the market. The company was founded by Vadim Bichko and is headquartered in San Diego, CA. | Commercial Services |
Teal Ventures Management LLC
Teal Ventures Management LLC Investment ManagersFinance Teal Ventures Management LLC (Teal Ventures) is a venture capital firm founded by Nikolay Savchuk, Ron Demuth, and Eddie Rodriguez in 2018. The firm Headquartered in San Diego, California. | Finance |
Viriom, Inc.
Viriom, Inc. Miscellaneous Commercial ServicesCommercial Services Viriom, Inc. is a biotechnology company based in San Diego, CA. The company focuses on developing innovative therapies for infectious diseases, including HIV and COVID-19. Viriom's mission is to improve the lives of patients by providing effective and accessible treatments. Iain David Dukes has been the CEO of the company since 2019, leading the team in their efforts to advance the development of their pipeline and bring new therapies to market. | Commercial Services |
